

Not for release to US wire services or distribution in the United States

ASX RELEASE

Special Instructions for Shareholders to access SPP documents due to Covid-19 restrictions

Wellington, NZ, 21st April 2020: Volpara Health Technologies Limited (**Volpara**; ASX: VHT), a medical technology company whose cancer screening software platform assists in the delivery of personalised patient care, provides an urgent reminder to all shareholders to update their contact details via Volpara's share registry to ensure they receive SPP documentation and application forms in a timely manner.

OVERVIEW

- **Volpara has announced today the successful completion of a placement to eligible investors raising A\$28m**
- **Concurrently with completion of the placement, Volpara has announced the launch of a A\$7m underwritten Share Purchase Plan ("SPP")**
- **All shareholders with a registered address in Australia and New Zealand are invited to participate in the SPP and apply for up to A\$30,000 (equivalent to approximately NZ\$31,500) in new shares at A\$1.30 per share (the same issue price as the placement)**
- **The SPP offer will only be open for two weeks between Tuesday, 28 April 2020 and 5.00pm (Sydney time) on Monday, 11 May 2020**
- **Due to current delays with postage in Australia and New Zealand due to Covid-19, all shareholders are encouraged to ensure their contact details are up to date, and that they provide an email address to Volpara's share registry, Boardroom Limited, via www.investorserve.com.au**
- **Separate instructions for New Zealand resident shareholders unable to use BPAY®, to allow payment by international electronic funds transfer, will be sent to, and made available to, New Zealand resident shareholders on www.investorserve.com.au**
- **The SPP is due to open on Tuesday 28 April 2020 - You will be able to view and/or download your personalised SPP Application Form and the SPP Terms and Conditions, and if you are a New Zealand resident shareholder the separate EFT instructions via www.investorserve.com.au after 11.00am on Tuesday 28 April**
- **A dedicated shareholder information phone line has been set up should you have any queries (normal business hours only): 1300 767 760 (within Australia) and +61 2 9290 9600 (outside Australia)**

Given the current delays with postage in Australia and New Zealand due to Covid-19, you are strongly encouraged to ensure that your contact details are up to date, and that you have provided an up to date email address, to Volpara's share registry, Boardroom Limited.

To be able to provide your email address so that you receive all relevant SPP documents in a timely manner, and to also allow you to update details of your shareholding in Volpara from time to time, if you have not already set up an account with Boardroom Limited, you will need to do so by following the steps below:

1. Go to **www.investorserve.com.au**
2. On the right-hand side of the web page click on **'Register Now'**.
3. Fill in the below information.

- **Issuer** – Enter the ASX code for Volpara Health Technologies Limited (**VHT**). You will need to select it from the drop-down box that appears when you enter the issuer name.
 - **Holding Type** – If you have a HIN number please select CHESS, if you have an SRN number please select Issuer Sponsored.
 - **Reference Number** – Enter either your HIN or SRN (This is available on your Holding Statement that will have been sent to you previously by the Company's share registry). Please note the share registry will not accept an internal reference number starting with an S, if you cannot locate your reference number please contact the share registry on the information line and it will be able to assist you with obtaining it). **Do not enter the preceding letter or zero's when entering your SRN or HIN.**
 - **Name** – Enter one name from your registered name as found on your Holding Statement. (e.g. for all the examples, please only enter Smith – John Smith – John Smith and Jane Smith – John Smith PTY LTD).
 - **Postcode** or **Country** (if outside Australia).
4. Once you have completed the steps above click '**Register**'.
 5. Click either mobile or email, then select 'Request Security Verification'. This will send a code to your mobile or the email address you have provided to continue your registration.
 6. Complete mobile or email verification step, by entering the code texted to your mobile or sent to your email.
 7. Create a unique '**Username**' (the username can contain a combination of letters, number and the following special characters ! @ # \$ % ^ & * () _ + - = an email address cannot be used as a username).
 8. Create a unique '**Password**' (your new password must contain at least: one upper case character; one lower case character; one number and the following special characters ! @ # \$ % ^ & * () _ + - =
 9. Enter your date of birth and create 3 unique security questions.
 10. **Tick** "I have read and accept the terms and conditions".
 11. Select **Activate Account**'.

PLEASE ACTION AS SOON AS POSSIBLE – ONCE ACTIVATED THIS WILL ALLOW YOU TO RECEIVE ALL RELEVANT SPP DOCUMENTS IN A TIMELY MANNER.

The SPP is scheduled to open on Tuesday 28 April 2020

You will be able to view and/or download your personalised SPP Application Form and the SPP Terms and Conditions via www.investorserve.com.au after 11.00am on Tuesday 28 April.

Separate instructions for New Zealand residents unable to use BPAY®, to allow payment by international electronic funds transfer, will be sent to New Zealand resident shareholders, and will also be available via www.investorserve.com.au

To view or download your SPP Application Form and the SPP Terms and Conditions go to:

- **For registered users**, go to www.investorserve.com.au then enter your username and password using the Registered User Access. Select My Portfolio and then Online Statements/Advices.



- **For unregistered users**, go to www.investorserve.com.au then Individual Investment Access. Your personalised SPP Application Form is available under the My Portfolio>Online Statements/Advices menu.

Shareholder information phone line (normal business hours only): 1300 767 760 (within Australia) and +61 2 9290 9600 (outside Australia)

ENDS.

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Volpara Health Technologies Limited, CEO Dr Ralph Highnam, and CFO & Company Secretary Craig Hadfield.

For further information, please contact:

Ralph Highnam, CEO

Kyahn Williamson

Volpara Health Technologies

WE Communications

ralph.highnam@volparasolutions.com

kwilliamson@we-worldwide.com

t: +64 21 149 0541

t: +61 3 9866 4722

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS, a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.

For more information, visit www.volparasolutions.com.